Neurocrine

Neurocrine Biosciences is a pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for neurological and endocrine-related diseases. Founded in 1992, the company is headquartered in San Diego, California. Neurocrine Biosciences has a strong research and development pipeline, with a particular emphasis on targeting G protein-coupled receptors (GPCRs) and nuclear receptors.

The company's most prominent product is Ingrezza (valbenazine), which is used for the treatment of tardive dyskinesia and chorea associated with Huntington's disease. Tardive dyskinesia is a movement disorder characterized by involuntary, repetitive, and purposeless movements. Huntington's disease is a progressive neurodegenerative disorder. Neurocrine Biosciences also has other candidates in various stages of clinical development for conditions such as congenital adrenal hyperplasia, endometriosis, and uterine fibroids.

Neurocrine Biosciences has established itself as a significant player in the neuroscience and endocrinology fields. Their strategy involves identifying unmet medical needs and developing targeted therapies with a deep understanding of underlying biological mechanisms. The company collaborates with academic institutions and other pharmaceutical companies to advance its research and development efforts. Their commitment to scientific innovation aims to improve the lives of patients suffering from complex and often debilitating diseases.